New research shows that the macrophage enzyme MMP14 generates soluble semaphorin 4D, which helps build an immunosuppressive tumor microenvironment and excludes anti-cancer T cells. The study links a specific myeloid mechanism to a broader immune-evading phenotype, highlighting MMP14–semaphorin signaling as a potential combination immunotherapy target.